Pulse Biosciences Inc (PLSE NASDAQ) stock market data APIs
$16.8858
0.15(0.9%)
as of May 22, 2025
Try our APIs with
free plan!
Pulse Biosciences Inc Financial Data Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Prev. Close
16.8858
Open
17.0392
High
17.3182
Low
16.5526
52 wk Range
9.7-25
Market Cap
1 134 M
Shares Outstanding
67 274 K
Revenue
-9 000
EPS
-0.2502
Beta
1.601
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Pulse Biosciences Inc data using free add-ons & libraries
Get Pulse Biosciences Inc Fundamental Data
{
"General": {
"Code": "PLSE",
"Type": "Common Stock",
"Name": "Pulse Biosciences Inc",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG00BRBHVD0",
"ISIN": null,
"CUSIP": null,
"CIK": "0001625101",
"EmployerIdNumber": "46-5696597",
"FiscalYearEnd": "December",
"IPODate": "2016-05-18",
"InternationalDomestic": "Domestic",
"Sector": "Healthcare",
"Industry": "Medical Instruments & Supplies",
"HomeCategory": "Domestic",
"IsDelisted": false,
"Description": "Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Car..."
}
}Pulse Biosciences Inc Fundamental data includes:
- Net Revenue: -9 000
- EBITDA: -62 524 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-05
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Pulse Biosciences Inc News
New
Insiders of Pulse Biosciences, Inc. (NASDAQ:PLSE) must be disappointed as stock fell 26% after recent purchases
Key Insights Pulse Biosciences' significant insider ownership suggests inherent interests in company's expansion The largest shareholder of the company is Robert Duggan with a 68% stake Insiders have...
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
HAYWARD, Calif., January 02, 2024--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation ...
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif., December 20, 2023--(BUSINESS WIRE)--Pulse...
Executive Chairman of Pulse Biosciences Robert Duggan Buys More Stock
Pulse Biosciences, Inc. (NASDAQ:PLSE) shareholders (or potential shareholders) will be happy to see that the Executive Chairman, Robert Duggan, recently bought a whopping US$2.0m worth of stock, at a ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
